Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder

Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder

BackgroundEpstein–Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Rituximab has been proven to dramatically improve the prognosis of patients with EBV reactivation...

Full description

Bibliographic Details
Main Authors: Nan Yan, Na Wang, Peiling Zhang, Gaoxiang Wang, Xia Mao, Dan Peng, Dong Kuang, Liting Chen, Li Zhu, Jianfeng Zhou, Yicheng Zhang, Yang Cao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
CAR-T
HSCT
PTLD
EBV
ALL
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.709370/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.709370/full

Similar Items